Breast cancer vaccines: Current research and future prospects

Expert Review of Vaccines

Volumn 1, Issue 1, 2002, Pages 29-34

  Cameron, David A ^a  

^a WESTERN GENERAL HOSPITAL   (United Kingdom)

Author keywords

Breast cancer; Vaccines

Indexed keywords

ANTINEOPLASTIC AGENT; CANCER VACCINE; CYCLOPHOSPHAMIDE; MUCIN 1; PACLITAXEL; SYNTHETIC PEPTIDE; THERATOPE; TUMOR ANTIGEN;

BREAST CARCINOMA; CANCER IMMUNOTHERAPY; CANCER PREVENTION; CELL ACTIVATION; CELLULAR IMMUNITY; CLINICAL TRIAL; CORRELATION ANALYSIS; DRUG TARGETING; DRUG TOLERABILITY; GENE OVEREXPRESSION; GENE SEQUENCE; HUMAN; IMMUNE SYSTEM; IMMUNOCOMPETENT CELL; IMMUNOLOGICAL MEMORY; MOLECULAR CLONING; NONHUMAN; ONCOGENE NEU; PRIORITY JOURNAL; REVIEW; SEQUENCE ANALYSIS; TUMOR REGRESSION; VACCINE PRODUCTION;

BREAST NEOPLASMS; CA-15-3 ANTIGEN; CANCER VACCINES; FEMALE; HUMANS; IMMUNOTHERAPY; PEPTIDE FRAGMENTS; RECEPTOR, ERBB-2; VACCINATION;

EID: 0038176240     PISSN: 14760584     EISSN: None     Source Type: Journal    
DOI: 10.1586/14760584.1.1.29     Document Type: Review

References (47)

1. Ioannides CG, Fisk B, Jerome KR et al. Cytotoxic T-cells from ovarian malignant tumors can recognize polymorphic epithelial mucin core peptides. J. Immunol. 151(7), 3693-3703 (1993).
2. Disis ML, Calenoff E, McLaughlin G et al. Existent T-cell and antibody immunity to HER-2/neu protein in patients with breast cancer. Cancer Res. 54(1), 16-20 (1994).
3. Disis ML, Pupa SM, Gralow JR et al. Hightiter HER-2/neu protein-specific antibody can be detected in patients with early-stage breast cancer. J. Clin. Oncol. 15(11), 3363-3367 (1997).
4. Toso JF, Oei C, Oshidari F et al. MAGE-1-specific precursor cytotoxic T-lymphocytes present among tumor-infiltrating lymphocytes from a patient with breast cancer: characterization and antigen-specific activation. Cancer Res. 56(1), 16-20 (1996).
5. Stewart T, Tsai SC, Grayson H, Henderson R, Opelz G. Incidence of de novo breast cancer in women chronically immunosuppressed after organ transplantation. Lancet 346(8978), 796-798 (1995).
6. Burchell J, Gendler S, Taylor-Papadimitriou J et al. Development and characterization of breast cancer reactive monoclonal antibodies directed to the core of the human milk mucin. Cancer Res. 47, 5476-5482 (1987).
7. Zotter S, Hageman PC, Lossnitzer A, Mooi WJ, Kilgers J. Tissue and Tumour distribution of human polymorphic epithelial mucin. Cancer Rev. 11, 55-101 (1988).
8. Burchell J, Taylor-Papadimitriou J, Boshell M, Gendler S, Duhig TA. A short sequence, within the amino acid tandem repeat of a cancer-associated mucin, contains immunodominant epitopes. Int. J. Cancer 44, 691-696 (1989).
9. von Mensdorff-Pouilly S, Verstraeten AA, Kenemans P et al. Survival in early breast cancer patients is favorably influenced by a natural humoral immune response to polymorphic epithelial mucin. J. Clin. Oncol 18(3), 574-583 (2000).
10. Agrawal B, Krantz MJ, Reddish MA, Longenecker BM. Cancer-associated MUC1 mucin inhibits human T-cell proliferation, which is reversible by IL-2. Nature Med 4(1), 43-49 (1998).
11. Agrawal B, Reddish MA, Krantz MJ, Longenecker BM. Does pregnancy immunise against breast cancer? Cancer Res. 55, 2257-2261 (1995).
12. Apostolopoulos V, Popovski V, McKenzie IFC. Cyclophosphamide enhances the CTL precursor frequency in mice immunized with MUC1-mannan fusion protein (M-FP). J. Immunother. 21, 109-113 (1998).
13. Apostolopoulos V, Xing PX, McKenzie IFC. Murine immune response to cells transfected with human MUCI: immunization with cellular and synthetic antigens. Cancer Res. 54, 5186-5193 (1994).
14. Ding L, Lalani EN, Reddish M et al. Immunogenicity ofsynthetic peptides related to the core peptide sequence encoded by the human MUC1 mucin gene: effect ofimmunization on the growth of murine mammary adenocarcinoma cells transfected with the human MUC1 gene. Cancer Immunol. Immunother. 36, 9-17 (1993).
15. Graham RA, Burchell J, Beverley P, Taylor-Papadimitriou J. Intramuscular immunization with MUC1 cDNA can protect C57 mice challenged with MUC1-expressing syngeneic mouse tumour cells. Int. J. Cancer 65, 664-670 (1996).
16. Zhang S, Greber LA, Helling F et al. Augmenting the immunogenicity of synthetic MUC1 peptide vaccines in mice. CancerRes. 56, 3315-3319 (1996).
17. Gilewski T, Adluri S, Ragupathi G et al. Vaccination of high-risk breast cancer patients with mucin-1 (MUC1) keyhole limpet hemocyanin conjugate plus QS-21. Clin. Cancer Res. 6(5), 1693-1701 (2000).
18. Karanikas V, Thynne G, Mitchell P et al. Mannin mucin-1 peptide immunization: influence of cyclophosphamide and the route of injection. J. Immunother. 24(2), 172-183 (2001).
19. Carmon L, El-Shami KM,Paz A et al. Novel breast-tumor-associated MUC1-derived peptides: characterization in Db-/- x β2 microglobulin (β2m) null mice transgenic for a chimeric HLA-A2.1/Db-β2 microglobulin single chain. Int. J. Cancer 85(3), 391-397 (2000).
20. Pietersz GA, Li W, Osinski C, Apostolopoulos V, McKenzie IF Definition of MHC-restricted CTL epitopes from non-variable number of tandem repeat sequence of MUC1. Vaccine 18(19), 2059-2071 (2000).
21. Vogel C, Sandmaier B, Burris H et al. THERATOPETM (STn-KLH) with Detox™-B stable emulsion for treatment of metastatic breast cancer following first-line chemotherapy. Proc. Ann. Meet. Am. Soc. Clin. Oncol. 18, A1761 (1999).
22. Sandmaier BM, Oparin DV, Holmberg LA et al. Evidence of a cellular immune response against sialyl-Tn in breast and ovarian cancer patients after high-dose chemotherapy, stem cell rescue and immunization with Theratope STn-KLH cancer vaccine. J. Immunother. 22(1), 54-66(1999).
23. Miles DW, Towlson KE, Graham R et al. A randomised Phase II study of sialyl-Tn and DETOX-B adjuvant with or without cyclophosphamide pretreatment for the active specific immunotherapy of breast cancer. Br. J. Cancer 74(8), 1292-1296 (1996).
24. MacLean GD, Miles DW, Rubens RD, Reddish MA, Longenecker BM. Enhancing the effect of THERATOPE STn-KLH cancer vaccine in patients with metastatic breast cancer by pretreatment with low-dose intravenous cyclophosphamide. J. Immunother. Emphasis Tumor Immunol. 19(4), 309-316 (1996).
25. Holmberg LA, Oparin DV, Gooley T et al. Clinical outcome of breast and ovarian cancer patients treated with high-dose chemotherapy, autologous stem cell rescue and THERATOPE STn-KLH cancer vaccine. Bone Marrow Transplant. 25(12), 1233-1241 (2000).
26. Scholl SM, Balloul JM, Le Goc G et al. Recombinant vaccinia virus encoding human MUC1 and IL2 as immunotherapy in patients with breast cancer. J. Immunother. 23(5), 570-580 (2000).
27. Plunkett TA, Windmill E, Acres RB, Taylor-Papadimitriou J, Miles DW. A Phase II study of a gene-modified vaccinia virus expressing MUC1 and II-2 (TG1031) in patients with metastatic breast cancer. Br. J. Cancer 85(Suppl. 1), 25 (2001).
28. Nussey F, Waterfall M, Samuel K, Atkinson A, Leonard P, Autologous MUC-1 pulsed dendritic cells are a safe, feasible treatment approach in patients with cancer and are associated with cellular immune responses. Br. J Cancer 85(Suppl. 1), 26 (2001).
29. Correa I, Plunkett TA. Update on HER-2 as a target for cancer therapy HER2/neu peptides as tumour vaccines for T-cell recognition. Breast Cancer Res. 3, 399-403 (2001).
30. Disis ML, Knutson KL, Schiffman K, Rinn K, McNeel DG. Pre-existent immunity to the HER-2/neu oncogenic protein in patients with HER-2/neu overexpressing breast and ovarian cancer. Breast Cancer Res. Treat 62(3), 245-252 (2000).
31. Disis ML, Schiffman K, Gooley TA et al. Delayed-type hypersensitivity response is a predictor of peripheral blood T-cell immunity after HER-2/neu peptide immunization. Clin. Cancer Res. 6(4), 1347-1350 (2000).
32. Brossart P, Wirths S, Stuhler G et al. Induction of cytotoxic T-lymphocyte responses in vivo after vaccinations with peptide-pulsed dendritic cells. Blood 96(9), 3102-3108 (2000).
33. Disis ML, Grabstein KH, Sleath PR, Cheever MA. Generation of immunity to the HER-2/neu oncogenic protein in patients with breast and ovarian cancer using a peptide-based vaccine. Clin. Cancer Res. 5(6), 1289-1297 (1999).
34. Knutson KL, Schifffman K, Rinn K, Disis ML. Immunotherapeutic approaches for the treatment ofbreast cancer. J. Mammary Gland Biology Neoplasia 4(4), 353-365 (1999).
35. Murray JL, Przepiorka D, Ioannides CG. Clinical trials of HER-2/neu-specific vaccines. Semin. Oncol. 27(6 Suppl. 11), 71-75 (2000).
36. Zaks TZ, Rosenberg SA. Immunization with a peptide epitope (p369-377) from HER-2/neu leads to peptide-specific cytotoxic T-lymphocytes that fail to recognize HER-2/neu+ tumors. Cancer Res. 58(21), 4902-4908 (1998).
37. Dakappagari NK, Douglas DB, Triozzi PL, Stevens VC, Kaumaya PT. Prevention of mammary tumors with a chimeric HER-2 B-cell epitope peptide vaccine. Cancer Res. 60(14), 3782-3789 (2000).
38. Yip YL, Smith G, Koch J, Dubel S, Ward RL Identification of epitope regions recognized by tumor inhibitory and stimulatory antiErbB-2 monoclonal antibodies: implications for vaccine design. J. Immunol. 166(8), 5271-5278 (2001).
39. Scanlan MJ, Jager D. Challenges to the development of antigen-specific breast cancer vaccines. Breast Cancer Res. 3(2), 95-98(1902).
40. Machiels JP, Reilly RT, Emens LA et al. Cydophosphamide, doxorubicin and paclitaxel enhance the antitumor immune response of granulocyte/macrophage-colony stimulating factor-secreting whole-cell vaccines in HER-2/neu tolerized mice. Cancer Res. 61(9), 3689-3697 (2001).
41. Apostolopoulos V, Pietersz GA, McKenzie IE MUC1 and breast cancer. Curr. Opin. Mol. Ther. 1(1), 98-103 (1999).
42. Bhattacharya-Chatterjee M, Chatterjee SK, Foon KA. The anti-idiotype vaccines for immunotherapy. Curr. Opin. Mol. Ther. 3(1), 63-69 (2001).
43. Borden EC, Esserman L, Linder DJ, Campbell MJ, Fulton AM. Biological therapies for breast carcinoma: concepts for improvement in survival. Semin. Oncol. 26(4 Suppl. 12), 28-40 (1999).
44. Jager E, Jager D, Knuth A. Strategies for the development of vaccines to treat breast cancer. Rec. Res. Cancer Res. 152, 94-102 (1998).
45. Knutson KL, Schiffman K, Disis ML. Immunization with a HER-2/neu helper peptide vaccine generates HER-2/neu CD8 T-cell immunity in cancer patients. J. Clin. Invest. 107(4), 477-484 (2001).
46. Morse MA. Technology evaluation: Theratope, Biomira, Inc. Curr. Opin. Mol. Ther. 2(4), 453-458 (2000).
47. von Mensdorff-Pouilly S, Snijdewint FG, Verstraeten AA, Verheijen RH, Kenemans P. Human MUC1 mucin: a multifaceted glycoprotein. Int. J. Biol. Markers 15(4), 343-356 (2000).